Redwood City, CA, United States of America

Sandra M Zurawski

This inventor holds 40 USPTO granted patents and 16 published patent applications, plus 3 CIPO patents and 9 EPO patents, primarily in Immunotherapy Innovations. Top assignees: Baylor Research Institute, Schering Corporation, National Institute of Health and Medical Research. Active years: 1991-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Sandra M Zurawski. Retrieved from https://idiyas.com/inventor/sandra-m-zurawski

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 40 (Patent Applications = 16)

% Patents Active = 90.0

CIPO Patents = 3 (Patent Applications = 2)

EPO Patents = 9 (Patent Applications = 13)

Average Co-Inventor Count = 4.2

ph-index = 10

Forward Citations = 342(Granted Patents)

Location History:

Redwood City, CA (US) (1991 - 1997)
San Juan Bautista, CA (US) (2002 - 2011)
Midlothian, TX (US) (2011 - 2024)

Company Filing History:

33 out of 96

Baylor Research Institute

National Institute of Health and Medical Research

patents

4. 4 out of 35

Université Paris Est Creteil Val De Marne

patents

5. 3 out of 331

Assistance Publique-Hopitaux De Paris

patents

where one patent can have more than one assignee

Years Active: 1991-2026

Loading Chart...

Areas of Expertise:

Immunotherapy

HPV Vaccines

Anti-CD40 Antibodies

Dendritic Cells

Fusion Proteins

Cytokines

T Cell Activation

Autoimmune Treatments

HIV Prevention

Inflammatory Conditions

Antigen-Presenting Cells

Therapeutic Agents

40 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12714745 - AGENTS THAT ENGAGE ANTIGEN-PRESENTING CELLS THROUGH DENDRITIC CELL ASIALOGLYCOPROTEIN RECEPTOR (DC-ASGPR) (2026-08-25),

2. 12576147 - RECOMBINANT PROTEINS WITH CD40 ACTIVATING PROPERTIES (2026-03-17),

3. 12214034 - Vaccines against HPV and HPV-related diseases (2025-02-04),

4. 12016915 - Agents that engage antigen-presenting cells through dendritic cell asialoglycoprotein receptor (DC-ASGPR) (2024-06-25),

5. 11957734 - Methods and compositions for treating autoimmune and inflammatory conditions (2024-04-16),

6. 11806390 - Fusion proteins comprising an anti-CD40 antibody and cancer antigens (2023-11-07),

7. 11717567 - Vaccines against HPV and HPV-related diseases (2023-08-08),

8. 11267895 - Nucleic acids encoding anti-CD40 antibodies (2022-03-08),

9. 11219683 - Methods and compositions for treating and preventing HIV (2022-01-11),

10. 10993990 - Methods and compositions for treating autoimmune and inflammatory conditions (2021-05-04),

11. 10980869 - Fusion proteins comprising an anti-CD40 antibody and cancer antigens (2021-04-20),

12. 10940195 - Vaccines against HPV and HPV-related diseases (2021-03-09),

13. 10722572 - Methods and compositions for treating and preventing HIV (2020-07-28),

14. 10683361 - Anti-CD40 antibodies (2020-06-16),

15. 10610585 - Methods and compositions for treating and preventing HIV (2020-04-07),

Title: Innovations in HPV Vaccination: The Contributions of Sandra M. Zurawski

Introduction

Sandra M. Zurawski, based in Redwood City, CA, is a leading inventor in the field of biotechnology and vaccines. With an impressive portfolio of 38 patents, Zurawski has made significant strides in developing innovative vaccines targeting human papillomavirus (HPV) and its related diseases.

Latest Patents

Zurawski's latest patents focus on vaccines against HPV and HPV-related diseases. These novel vaccines incorporate anti-human dendritic cell surface receptor antibodies, particularly CD40, along with E6/7 proteins from HPV types 16 and 18. Notably, the technology extends beyond these two strains and can create vaccines for E6/7 proteins from any HPV type. The designed HPV vaccines are engineered to effectively target dendritic cells and other antigen presenting cells, aiming to induce strong immune responses from both CD4+ and CD8+ T cells. The applications of these vaccines are dual-faceted, serving both as a preventive measure against HPV infection and as a treatment for HPV-related diseases, including various cancers.

Career Highlights

Sandra Zurawski has worked with prominent organizations, including the Baylor Research Institute and Schering Corporation. Her career reflects a commitment to advancing medical research and developing innovative solutions to combat infectious diseases.

Collaborations

Collaboration has been a crucial element in Zurawski's career. She has worked alongside notable researchers such as Gerard Zurawski and SangKon Oh, furthering advancements in the field of vaccine development through shared expertise and innovation.

Conclusion

Sandra M. Zurawski's contributions to vaccine technology, particularly in relation to HPV, exemplify the important intersection of scientific research and practical application. With her extensive portfolio and collaborative efforts, Zurawski remains a pivotal figure in the ongoing fight against HPV-related diseases, paving the way for future innovations in healthcare.

Profile summary based on public USPTO records.